Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 413-416

  Zaaijer, H L ^a,b   Takkenberg, R B ^b   Weegink, C J ^b   Rebers, S P H ^a   Menting, S ^a   Reesink, H W ^b   Schinkel, J ^a   Molenkamp, R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral therapy; HBV; Mutation; Subpopulation

Indexed keywords

ADEFOVIR; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS RESISTANCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG COMBINATION; DRUG EFFECT; GENETICS; MISSENSE MUTATION; VIRUS LOAD;

HEPATITIS B VIRUS;

ADENINE; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MUTATION, MISSENSE; PHOSPHONIC ACIDS; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 60049097893     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21401     Document Type: Article

References (19)

1. Bartholomeusz A, Schaefer S. 2004. Hepatitis B virus genotypes: Comparison of genotyping methods. Rev Med Virol 14:13-16.
2. Bartholomeusz A, Tehan BG, Chalmers DK. 2004. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 9:149-160.
3. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2002. The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 76:3248-3256.
4. Buti M, Elefsiniotis R, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R. 2007. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 47:366-372.
5. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 279:509-516.
6. Dimou E, Papadimitropoulos V, Hadziyannis SJ. 2007. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag 3:1077-1086.
7. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44:283-290.
8. Götte M, Arion D, Parniak MA, Wainberg MA. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 74:3579-3585.
9. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV. 2008. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol 80:1160-1170.
10. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. 2005. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42:1414-1419.
11. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunetto M, Andreone P, Sagnelli E, Fagiuoli S, Mazzella G, Raimondo G, Gaeta G, Ascione A. Adefovir Study Group on behalf of the AISF1. 2006. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 44:693A-694A.
12. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine; a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451.
13. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J.Cirrhosis Asian Lamivudine Multicentre Study Group. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
14. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 179:92-100.
15. Reijnders JGP, Janssen HLA. 2008. Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? J Hepatol 48:383-386.
16. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 4:87-94.
17. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 46:3437-3446.
18. Yadav V, Chu CK. 2004. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: A molecular dynamics study. Bioorg Med Chem Lett 14:4313-4317.
19. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. 2008. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. J Hepatol 48:923-931.